Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration
Daniel Barthelmes, Anna Campain, Nguyen Phuc, Jennifer J Arnold, Ian L McAllister, Judy M Simpson, Alex P Hunyor, Robyn Guymer, Rohan W Essex, Nigel Morlet, Mark C Gillies
British Journal of Ophthalmology | BMJ PUBLISHING GROUP | Published : 2016
AIMS: To examine 12-month outcomes of eyes switching from intravitreal ranibizumab to aflibercept for neovascular age-related macular degeneration (nAMD). METHODS: Database observational study of eyes with nAMD tracked by the Fight Retinal Blindness outcome registry that received ranibizumab for at least 12 months before switching to aflibercept and followed for at least 12 months after the switch. Visual acuity (VA) recorded at 12 months after the switch was analysed using locally weighted scatterplot smoothing curves. Lesion activity was graded according to a prospectively identified definition. Main outcomes were change in VA and treatment intervals 12 months after the treatment switch. S..View full abstract
This work was supported by a grant from the Royal Australian NZ College of Ophthalmologists Eye Foundation (2007-2009) and a grant from the National Health and Medical Research Council, Australia (NHRMC 2010-1012).